dChan - Q Origins Project Archive

on the 15th anniversary of I Am Legend

Cancer mRNA vaccine completes pivotal trial

https://www.bbc.com/news/health-63959843

Researchers say they have successfully completed a trial of a personalised cancer vaccine that uses the same messenger-RNA technology as Covid jabs.

The experimental vaccine, made by Moderna and MSD, is designed to prime the immune system to seek and destroy cancerous cells.

Doctors hope work such as this could lead to revolutionary new ways to fight skin, bowel and other types of cancer.

Moderna and MSD called it "a new paradigm" moment.

Other pharmaceutical companies are looking to run similar studies.

But this is the first phase-IIb randomised clinical trial to test the investigational mRNA vaccine in patients.

Could Covid vaccine technology crack cancer?

Patients taking Keytruda for advanced melanoma were less likely to die, or have the skin cancer reoccur, if they also had the jab, mRNA-4157/V940, Moderna and MSD said.

The findings, in 157 patients, have not yet been scrutinised by independent experts or regulators.

More trials will be needed to check how effective the treatment might be.

Moderna's chief medical officer Paul Burton said: "This is a significant finding. It's the first randomised-trial testing of an mRNA therapeutic in cancer patients.

"It's shown a 44% relative reduction in the risk of dying of cancer or having your cancer progress. That's an important finding and I think it has the potential to be a new paradigm in the treatment of cancer patients."

'Very exciting'

Tailormade to match each patient's cancer, the vaccine is very expensive to make - although, the company has not named a price.

Prof Alan Melcher from The Institute of Cancer Research said: "There's no question, this is very exciting. These results show the feasibility of making and delivering personalised vaccines to treat cancer, and that the vaccine can add benefit to current treatments.

"These results establish the principle that this complex technology is doable."

Consultant colorectal surgeon at the University of Birmingham Mr Andrew Beggs said: "Although early data, it is very encouraging that this is a likely effective treatment option in the future.

"This advance is likely to have important implications for metastatic cancer patients in the future and opens a new therapeutic avenue for these patients."

Dr Sam Godfrey from Cancer Research UK, said: "There is unlikely to be a single cure for cancer and we must focus on ways to tailor treatment for patients. These results are grounds for optimism that the science which helped get us out of the pandemic could add another powerful treatment option for cancer in the future."

Anonymous ID: 6ab265 Dec. 14, 2022, 11:48 a.m. No.17942043 🗄️.is 🔗kun >>2722

https://twitter.com/lawrie_dr/status/1602971254142681088

Dr Tess Lawrie

@lawrie_dr

.

@TheBHF

The World Council for Health urgently requests a full statement from The British Heart Foundation. Were the harms of these injections known and covered up?

The #vaccine rollout must be stopped pending an urgent investigation

@iCharmaine

#mRNA

@ABridgen

@JamesfWells

Quote Tweet

James Freeman

@JamesfWells

·

Dec 13

🚨 BREAKING NEWS: A prominent leader of the British Heart Foundation has conspired to cover-up research linking mNRA jabs with heart inflammation, says British MP

@TheBHF @SteveBarclay @ABridgen

Show this thread

https://twitter.com/elonmusk/status/1325934016353214465

"[mRNA]basically makes the solutions to diseases a software problem"- Elon Musk

Sam 🕊

@SamTwits

·

Nov 9, 2020

The vaccine that

@tesla

are working on takes a similar approach to Pfizer and although slower to human trials, may be easier to scale, optimising the nucleic acid rather than chemical modification of the RNA. Any updates on this

@elonmusk

?

Elon Musk

@elonmusk

Replying to

@SamTwits

@SamTalksTesla

and

@Tesla

Tesla makes the RNA Bioreactor that can make vaccines / cures. CureVac has version 2 in use. Version 3 is under development.

Anonymous ID: 6ab265 Dec. 14, 2022, 11:55 a.m. No.17942076 🗄️.is 🔗kun >>2103 >>2722

>>17942066

https://www.teslarati.com/elon-musk-shares-tesla-mrna-microfactories-details/

Elon Musk shares details about Tesla’s mRNA microfactories for CureVac

Elon Musk shared some details about Tesla’s mRNA microfactories for CureVac’s COVID vaccine development recently. In February 2019, CureVac published a press release that referred to a bioreactor dubbed The RNA Printer. Musk’s recent tweet provided some details about the bioreactor Tesla developed for CureVac’s mRNA vaccine initiatives.

“Tesla makes the RNA Bioreactor that can make vaccines/cures. Curevac has Version 2 in use. Version 3 is under development. I do expect this to become an important product for the world, but probably not financially for Tesla,” Musk stated on Twitter as a response to an inquiry from Tesla owner-investor @SamTalksTesla.

Tesla makes the RNA Bioreactor that can make vaccines / cures. CureVac has version 2 in use. Version 3 is under development.

— Elon Musk (@elonmusk) November 9, 2020

Musk discussed Tesla’s partnership with CureVac in July 2020 and shared his thoughts about the potential of synthetic RNA and DNA. At the time, Musk referred to diseases as a “software problem.” With that perspective, Tesla seems more than capable of developing technology to manufacture mRNA vaccines at scale. Musk visited CureVac’s headquarters in Tübingen, Germany in September to discuss Tesla subsidiary Grohmann Automation’s contribution to the development of CureVac’s mRNA COVID vaccine.

mRNA vaccines are easier to produce and scale compared to traditional ones. Tesla’s RNA Bioreactor will come into play during the production stage of CureVac’s COVID vaccine, once it is approved. Due to the scalability of mRNA vaccines, Tesla’s RNA Bioreactor might play a key role in making CureVac’s COVID vaccine easily accessible to the public.

Last week, CureVac reported positive results in Phase 1 of its COVID vaccine candidate. “We are very encouraged by the interim Phase 1 data. It represents a critical milestone in our COVID-19 vaccine program and strongly supports the advancement of our vaccine candidate,” said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.

I do expect this to become an important product for the world, but probably not financially material for Tesla

— Elon Musk (@elonmusk) November 9, 2020

“Following further data readouts and discussion with regulatory authorities, we remain fully committed and on track to initiate a pivotal Phase 2b/3 trial before the end of 2020,” he added.

As of this writing, there have been no mRNA vaccines licensed for infectious disease because they are relatively new in the world of medicine. This new type of vaccine allows scientists to create synthetic mRNA, which contains the code for infectious proteins that create a virus’ molecules.

Vaccines that make synthetic mRNA cannot form a full virus, but it can develop enough of its parts to trigger the body’s immune system. The human body has innate immunity, which are defense systems we are born with, and acquired immunity, which develops over time as we come into contact with pathogens. Traditional vaccines work more with the acquired immune system, while mRNA vaccines have the potential to trigger the body’s innate immune system. Since it is incapable of developing full viruses, mRNA vaccine patients cannot spread the disease either.

Elon Musk shares details about Tesla’s mRNA microfactories for CureVac

Anonymous ID: 6ab265 Dec. 14, 2022, 11:57 a.m. No.17942083 🗄️.is 🔗kun >>2124

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine (CoVPN 3006)

https://beta.clinicaltrials.gov/study/NCT04811664

https://www.futuremedicine.com/doi/10.2217/fmb-2022-0014

Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients

Abstract

Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20 random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients & methods: In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms.

COVID-19 Pneumonia and Gut Inflammation: The Role of a Mix of Three Probiotic Strains in Reducing Inflammatory Markers and Need for Oxygen Support

https://www.mdpi.com/2077-0383/11/13/3758

settingsOrder Article Reprints

Open AccessArticle

COVID-19 Pneumonia and Gut Inflammation: The Role of a Mix of Three Probiotic Strains in Reducing Inflammatory Markers and Need for Oxygen Support

by Angela Saviano 1,Annalisa Potenza 2,Valentina Siciliano 3,Carmine Petruzziello 4ORCID,Claudia Tarli 2,Alessio Migneco 1,Flavia Nasella 1,Francesco Franceschi 1 andVeronica Ojetti 1,*ORCID

1

Emergency Medicine Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00165 Rome, Italy

2

Internal Medicine Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00165 Rome, Italy

3

Department of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00165 Rome, Italy

4

Emergency Medicine Department, Ospedale San Carlo di Nancy, 00165 Rome, Italy

*

Author to whom correspondence should be addressed.

J. Clin. Med. 2022, 11(13), 3758; https://doi.org/10.3390/jcm11133758

Received: 14 May 2022 / Revised: 25 June 2022 / Accepted: 26 June 2022 / Published: 28 June 2022

(This article belongs to the Section Gastroenterology & Hepatopancreatobiliary Medicine)

Download Browse Figures Review Reports Versions Notes

Abstract

Background: COVID-19 disease, which typically presents with respiratory symptoms, can trigger intestinal inflammation through SARS-CoV-2 replication in the gastrointestinal tract. Supplementation with probiotics may have beneficial effects on gut inflammation due to their analgesic and anti-inflammatory properties. The primary objective of our study was to evaluate the efficacy of a mix of three probiotic strains (Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302, and Lactobacillus acidophilus LA 201; Lactibiane Iki®) in the reduction in fecal calprotectin in patients with COVID-19 pneumonia, compared to a control group. The secondary aim was to evaluate the reduction in oxygen support and length of hospital stay in patients taking the probiotic mix. Patients and Methods: We conducted a prospective randomized controlled trial at Fondazione Policlinico Gemelli, Rome. We enrolled patients with COVID-19 interstitial pneumonia. One group received the probiotic mix twice a day for 10 days in addition to the standard COVID-19 therapy, and a second group received standard COVID-19 therapy without probiotics. We administered oxygen support (through Ventimask or Optiflow®) on days (D) 1, 3, 5, 7 and 10, and the level of fecal calprotectin between D3–D5 and D7–D10. Results: A total of 80 patients (44 M/36 F; mean age: 59.8 ± 17.3) were enrolled with a mean value of calprotectin at enrollment of 140 mg/dl. At D7–10, the probiotic group showed a 35% decrease in fecal calprotectin compared to 16% in the control group, a decrease in C-reactive protein (CRP) of 72.7% compared to 62%, and a slight but not significant decrease in oxygen support compared to the control group. Conclusion: Supplementation with a mix of probiotics for 10 days in patients with COVID-19 interstitial pneumonia significantly reduces inflammatory markers.

Conclusions

Our randomized controlled trial (RCT) showed thatsupplementation with a mix of three probiotic strains in patients with COVID-19 interstitial pneumonia and intestinal inflammation significantly reduced gut inflammatory markers. Other trials with a larger number of patients are needed to confirm these data.

What will it take for the media and public health bureaucrats to admit the mRNA vaccines have failed?

https://alexberenson.substack.com/p/what-will-take-for-the-media-and

It’s summer in Australia - but the country, where nearly every adult has been vaccinated, is now entering its fourth Covid wave.

In Switzerland, excess deaths since February have been confined exclusively to people over 65, who are also the only ones who have received mRNA boosters.

The story is similar in South Africa.

And Quebec.

In Taiwan, another country with near-total adult vaccine compliance, overall births have plunged and deaths skyrocketed in 2022. (Births are down significantly in most highly vaccinated countries, but the effect is particularly striking in East Asia, which is already in the early stages of demographic collapse.)

(Gee, I wonder. Whatever could the problem be?)

—

For the countries that used mRNA vaccines from Pfizer and Moderna to combat Covid, 2022 has been a year of profound disappointment.

Just one more example: Canada used social pressure and government mandates to reach levels of vaccine compliance well above the United States. About 89 percent of Canadian adults were fully vaccinated by fall 2021, and 60 percent received a booster.

The result: this has already been Canada’s worst year for Covid deaths, with 20 percent more Covid deaths in 2022 than either 2021 or 2020.

If that’s vaccine success, what would failure look like?

https://mobile.twitter.com/BernieSpofforth/status/1602633064773042177

Bernie's Tweets

@BernieSpofforth

AUSTRALIA - Melbourne has started installing defibrillators outside homes, making sure every resident has easy access.. to help with the increase in sudden cardiac arrests.

Oh …

30 million in UK ‘priced out of decent standard of living by 2024’

https://www.theguardian.com/business/2022/dec/12/30-million-in-uk-priced-out-of-decent-standard-of-living-by-2024

Thinktank blames rising prices, inflation and unemployment, and called for national living income.

Thirty million people in the UK will be unable to afford what the public considers to be a decent standard of living by the time the current parliament ends in 2024, according to a study.

The New Economics Foundation, a left-leaning thinktank, said rising prices, below-inflation increases in earnings and projected increases in unemployment would result in 43% of households lacking the resources to put food on the table, buy new clothes or treat themselves and their families – a 12 percentage point rise compared with 2019.

The NEF said its calculation that by 2024 almost 90% of single parents and 50% of workers with children would fall below a minimum income standard showed the need for a radical overhaul of the welfare system.

The thinktank called for universal credit to be scrapped and replaced by a national living income, a minimum below which no one could fall whether they were in or out of work. Under its proposal, more than two-thirds of the population would see their disposable incomes rise, with increases of more than 50% – or £500 a month – for the poorest households.

The £70bn-a-year plan would be funded by a more progressive tax system, it said, including the harmonisation of tax rates for income and wealth, extending national insurance to investment income, and abolishing the upper earnings limit for NICs.

Sam Tims, economist at the New Economics Foundation, said: “A decade of cuts, freezes, caps and haphazard migration between systems has left the UK with one of the weakest safety nets among developed countries.

“Millions of families were already living in avoidable deprivation and hardship but as we enter the greatest living standards crisis on modern records, the day-to-day experience of low-income families is set to become even more desperate.”

“We need a bold new way of providing income support that will help all people deal with the challenges presented by the fast-changing world we’re living in. A national living income would set an income floor that is enough to meet life’s essentials, which no one can fall below whether they are in or out of work.”

Official figures show that 22% of people in the UK are living below the poverty line because they are getting by on less than 60% of median household income.

The NEF definition of a decent living standard is based on work by another thinktank, the Joseph Rowntree Foundation, which asks people what they consider to be an acceptable minimum. The list covers eight categories: housing, domestic fuel, food and drink, clothing, household goods and services, health and personal care, transport and travel, and social and cultural participation.

The ”minimum income standard” varies depending on household type, but the average shortfall will have risen from £6,200 a year as of December 2019 to £10,000 by December 2024, the NEF said. It added that the MIS was used to calculate the so-called real living wage paid by companies like Ikea and KPMG, and football clubs like West Ham, Liverpool and Chelsea.

A government spokesperson said: “Universal credit offers a vital safety net to millions of people, enabling them to support themselves and their families while moving towards financial independence through employment.

“But we recognise that people are struggling with rising prices which is why we are protecting millions of those most in need with at least £1,200 of direct help this year, including £400 towards energy costs. Our immediate support for families also includes our energy price guarantee, saving around £900 for a typical household over winter.”

World Health Organization (WHO)

@WHO

ANNOUNCEMENT📢Dr Jeremy Farrar will become the new Chief Scientist of WHO. Currently, he is the Director of Wellcome Trust. Dr Farrar will join WHO in the second quarter of 2023.

🔗

https://mobile.twitter.com/WHO/status/1602607082758356993

Anonymous ID: 6ab265 Dec. 14, 2022, 12:17 p.m. No.17942181 🗄️.is 🔗kun >>2722

China food security: bumper grain harvest defies year full of challenges, and it could affect global food prices

https://www.scmp.com/economy/china-economy/article/3202992/china-food-security-bumper-grain-harvest-defies-year-full-challenges-and-it-could-affect-global-food

James Melville

@JamesMelville

·

Dec 13

The UK is the number one Core Voluntary Contributions Account (CVCA) contributor to the World Health Organisation (WHO) - spending more than 3 times more than any other country. ($135 million in 2020-2021).

https://mobile.twitter.com/JamesMelville/status/1602706065946189830

https://www.nbcnews.com/health/health-news/two-years-covid-vaccines-rcna57902

Two years after Covid vaccines rolled out, researchers are calling for newer, better options

>>17942029

>>17942218

>on the 15th anniversary of I Am Legend

>Cancer mRNA vaccine completes pivotal trial

https://pubmed.ncbi.nlm.nih.gov/33088593/

Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2

I Am Legend

"This adaptation also deviates significantly from the novel. In this version, the infection is caused by a vaccine originally intended to cure cancer. "